Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 44 entries
Sorted by: Best Match Show Resources per page
Early Cocking Phase Mechanics and Upper Extremity Surgery Risk in Starting Professional Baseball Pitchers.

Orthopaedic journal of sports medicine

Douoguih WA, Dolce DL, Lincoln AE.
PMID: 26665056
Orthop J Sports Med. 2015 Apr 22;3(4):2325967115581594. doi: 10.1177/2325967115581594. eCollection 2015 Apr.

BACKGROUND: Early cocking phase pitching mechanics may affect risk of upper extremity injury requiring surgery in professional baseball players.PURPOSE: To assess the occurrence of inverted-W arm positioning and early trunk rotation in Major League Baseball (MLB) pitchers and to...

Cite
Douoguih WA, Dolce DL, Lincoln AE. Early Cocking Phase Mechanics and Upper Extremity Surgery Risk in Starting Professional Baseball Pitchers. Orthop J Sports Med. 2015;3(4):2325967115581594doi: 10.1177/2325967115581594.
Douoguih, W. A., Dolce, D. L., & Lincoln, A. E. (2015). Early Cocking Phase Mechanics and Upper Extremity Surgery Risk in Starting Professional Baseball Pitchers. Orthopaedic journal of sports medicine, 3(4), 2325967115581594. https://doi.org/10.1177/2325967115581594
Douoguih, Wiemi A, et al. "Early Cocking Phase Mechanics and Upper Extremity Surgery Risk in Starting Professional Baseball Pitchers." Orthopaedic journal of sports medicine vol. 3,4 (2015): 2325967115581594. doi: https://doi.org/10.1177/2325967115581594
Douoguih WA, Dolce DL, Lincoln AE. Early Cocking Phase Mechanics and Upper Extremity Surgery Risk in Starting Professional Baseball Pitchers. Orthop J Sports Med. 2015 Apr 22;3(4):2325967115581594. doi: 10.1177/2325967115581594. eCollection 2015 Apr. PMID: 26665056; PMCID: PMC4622343.
Copy Download .nbib Format: NLM
Lemierre syndrome: once seen it can never be mistaken.

BMJ case reports

Abourazzak S, Zouagui A, Smaili L, Ouzaa H, Lamrani YM, Tizniti S, Elarqam L, Chaouki S, Atmani S, Bouharrou A, Hida M.
PMID: 21686487
BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.10.2008.1041. Epub 2009 Mar 05.

Lemierre syndrome is a rare but severe septicaemia due most frequently to Fusobacterium necrophorum, with primary foci in the head, internal jugular vein thrombosis and metastatic infections, mainly in the lungs. We report two cases of Lemierre syndrome admitted...

Cite
Abourazzak S, Zouagui A, Smaili L, et al. Lemierre syndrome: once seen it can never be mistaken. BMJ Case Rep. 2009;2009doi: 10.1136/bcr.10.2008.1041.
Abourazzak, S., Zouagui, A., Smaili, L., Ouzaa, H., Lamrani, Y. M., Tizniti, S., Elarqam, L., Chaouki, S., Atmani, S., Bouharrou, A., & Hida, M. (2009). Lemierre syndrome: once seen it can never be mistaken. BMJ case reports, 2009. https://doi.org/10.1136/bcr.10.2008.1041
Abourazzak, Sana, et al. "Lemierre syndrome: once seen it can never be mistaken." BMJ case reports vol. 2009 (2009). doi: https://doi.org/10.1136/bcr.10.2008.1041
Abourazzak S, Zouagui A, Smaili L, Ouzaa H, Lamrani YM, Tizniti S, Elarqam L, Chaouki S, Atmani S, Bouharrou A, Hida M. Lemierre syndrome: once seen it can never be mistaken. BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.10.2008.1041. Epub 2009 Mar 05. PMID: 21686487; PMCID: PMC3028603.
Copy Download .nbib Format: NLM
Treatment of Acute Proximal Anterior Cruciate Ligament Tears-Part 2: The Role of Internal Bracing on Gap Formation and Stabilization of Repair Techniques.

Orthopaedic journal of sports medicine

Bachmaier S, DiFelice GS, Sonnery-Cottet B, Douoguih WA, Smith PA, Pace LJ, Ritter D, Wijdicks CA.
PMID: 32064294
Orthop J Sports Med. 2020 Jan 28;8(1):2325967119897423. doi: 10.1177/2325967119897423. eCollection 2020 Jan.

BACKGROUND: The latest biomechanical studies on some form of internal bracing have shown improved stabilization for anterior cruciate ligament (ACL) repair, but gap formation and load-sharing function have not yet been reported.HYPOTHESIS: Internal bracing of an adjustable ACL repair...

Cite
Bachmaier S, DiFelice GS, Sonnery-Cottet B, et al. Treatment of Acute Proximal Anterior Cruciate Ligament Tears-Part 2: The Role of Internal Bracing on Gap Formation and Stabilization of Repair Techniques. Orthop J Sports Med. 2020;8(1):2325967119897423doi: 10.1177/2325967119897423.
Bachmaier, S., DiFelice, G. S., Sonnery-Cottet, B., Douoguih, W. A., Smith, P. A., Pace, L. J., Ritter, D., & Wijdicks, C. A. (2020). Treatment of Acute Proximal Anterior Cruciate Ligament Tears-Part 2: The Role of Internal Bracing on Gap Formation and Stabilization of Repair Techniques. Orthopaedic journal of sports medicine, 8(1), 2325967119897423. https://doi.org/10.1177/2325967119897423
Bachmaier, Samuel, et al. "Treatment of Acute Proximal Anterior Cruciate Ligament Tears-Part 2: The Role of Internal Bracing on Gap Formation and Stabilization of Repair Techniques." Orthopaedic journal of sports medicine vol. 8,1 (2020): 2325967119897423. doi: https://doi.org/10.1177/2325967119897423
Bachmaier S, DiFelice GS, Sonnery-Cottet B, Douoguih WA, Smith PA, Pace LJ, Ritter D, Wijdicks CA. Treatment of Acute Proximal Anterior Cruciate Ligament Tears-Part 2: The Role of Internal Bracing on Gap Formation and Stabilization of Repair Techniques. Orthop J Sports Med. 2020 Jan 28;8(1):2325967119897423. doi: 10.1177/2325967119897423. eCollection 2020 Jan. PMID: 32064294; PMCID: PMC6987493.
Copy Download .nbib Format: NLM
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants.

bioRxiv : the preprint server for biology

Cho H, Gonzales-Wartz KK, Huang D, Yuan M, Peterson M, Liang J, Beutler N, Torres JL, Cong Y, Postnikova E, Bangaru S, Talana CA, Shi W, Yang ES, Zhang Y, Leung K, Wang L, Peng L, Skinner J, Li S, Wu NC, Liu H, Dacon C, Moyer T, Cohen M, Zhao M, Lee FE, Weinberg RS, Douagi I, Gross R, Schmaljohn C, Pegu A, Mascola JR, Holbrook M, Nemazee D, Rogers TF, Ward AB, Wilson IA, Crompton PD, Tan J.
PMID: 33821267
bioRxiv. 2021 Apr 01; doi: 10.1101/2021.04.01.437942.

The emergence of SARS-CoV-2 variants that threaten the efficacy of existing vaccines and therapeutic antibodies underscores the urgent need for new antibody-based tools that potently neutralize variants by targeting multiple sites of the spike protein. We isolated 216 monoclonal...

Cite
Cho H, Gonzales-Wartz KK, Huang D, et al. Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants. bioRxiv. 2021;doi: 10.1101/2021.04.01.437942.
Cho, H., Gonzales-Wartz, K. K., Huang, D., Yuan, M., Peterson, M., Liang, J., Beutler, N., Torres, J. L., Cong, Y., Postnikova, E., Bangaru, S., Talana, C. A., Shi, W., Yang, E. S., Zhang, Y., Leung, K., Wang, L., Peng, L., Skinner, J., Li, S., Wu, N. C., Liu, H., Dacon, C., Moyer, T., Cohen, M., Zhao, M., Lee, F. E., Weinberg, R. S., Douagi, I., Gross, R., Schmaljohn, C., Pegu, A., Mascola, J. R., Holbrook, M., Nemazee, D., Rogers, T. F., Ward, A. B., Wilson, I. A., Crompton, P. D., & Tan, J. (2021). Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2021.04.01.437942
Cho, Hyeseon, et al. "Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2021.04.01.437942
Cho H, Gonzales-Wartz KK, Huang D, Yuan M, Peterson M, Liang J, Beutler N, Torres JL, Cong Y, Postnikova E, Bangaru S, Talana CA, Shi W, Yang ES, Zhang Y, Leung K, Wang L, Peng L, Skinner J, Li S, Wu NC, Liu H, Dacon C, Moyer T, Cohen M, Zhao M, Lee FE, Weinberg RS, Douagi I, Gross R, Schmaljohn C, Pegu A, Mascola JR, Holbrook M, Nemazee D, Rogers TF, Ward AB, Wilson IA, Crompton PD, Tan J. Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants. bioRxiv. 2021 Apr 01; doi: 10.1101/2021.04.01.437942. PMID: 33821267; PMCID: PMC8020967.
Copy Download .nbib Format: NLM
Whitening Efficacy of 3% Carbamide Peroxide Gel Activated by Lactoperoxidase.

International journal of dentistry

Khemiss M, Kallel I, Zouaghi H, Ben Khelifa M, Bagga S.
PMID: 34122550
Int J Dent. 2021 May 26;2021:7143623. doi: 10.1155/2021/7143623. eCollection 2021.

OBJECTIVE: The aim of this clinical study was to evaluate the effectiveness of a whitening toothpaste containing 3% carbamide peroxide and lactoperoxidase. RESULTS: Thirty-four volunteers were included. Δ CONCLUSION: Based on these results, it may be concluded that brushing...

Cite
Khemiss M, Kallel I, Zouaghi H, et al. Whitening Efficacy of 3% Carbamide Peroxide Gel Activated by Lactoperoxidase. Int J Dent. 2021;2021:7143623doi: 10.1155/2021/7143623.
Khemiss, M., Kallel, I., Zouaghi, H., Ben Khelifa, M., & Bagga, S. (2021). Whitening Efficacy of 3% Carbamide Peroxide Gel Activated by Lactoperoxidase. International journal of dentistry, 20217143623. https://doi.org/10.1155/2021/7143623
Khemiss, Mehdi, et al. "Whitening Efficacy of 3% Carbamide Peroxide Gel Activated by Lactoperoxidase." International journal of dentistry vol. 2021 (2021): 7143623. doi: https://doi.org/10.1155/2021/7143623
Khemiss M, Kallel I, Zouaghi H, Ben Khelifa M, Bagga S. Whitening Efficacy of 3% Carbamide Peroxide Gel Activated by Lactoperoxidase. Int J Dent. 2021 May 26;2021:7143623. doi: 10.1155/2021/7143623. eCollection 2021. PMID: 34122550; PMCID: PMC8172322.
Copy Download .nbib Format: NLM
Durable natural killer cell responses after heterologous two-dose Ebola vaccination.

NPJ vaccines

Wagstaffe HR, Susannini G, Thiébaut R, Richert L, Lévy Y, Bockstal V, Stoop JN, Luhn K, Douoguih M, Riley EM, Lacabaratz C, Goodier MR.
PMID: 33514756
NPJ Vaccines. 2021 Jan 29;6(1):19. doi: 10.1038/s41541-021-00280-0.

Natural killer (NK) cells are implicated among immune effectors after vaccination against viral pathogens, including Ebola virus. The two-dose heterologous Ebola virus vaccine regimen, adenovirus type 26.ZEBOV followed by modified vaccinia Ankara-BN-Filo (EBOVAC2 consortium, EU Innovative Medicines Initiative), induces...

Cite
Wagstaffe HR, Susannini G, Thiébaut R, et al. Durable natural killer cell responses after heterologous two-dose Ebola vaccination. NPJ Vaccines. 2021;6(1):19doi: 10.1038/s41541-021-00280-0.
Wagstaffe, H. R., Susannini, G., Thiébaut, R., Richert, L., Lévy, Y., Bockstal, V., Stoop, J. N., Luhn, K., Douoguih, M., Riley, E. M., Lacabaratz, C., & Goodier, M. R. (2021). Durable natural killer cell responses after heterologous two-dose Ebola vaccination. NPJ vaccines, 6(1), 19. https://doi.org/10.1038/s41541-021-00280-0
Wagstaffe, Helen R, et al. "Durable natural killer cell responses after heterologous two-dose Ebola vaccination." NPJ vaccines vol. 6,1 (2021): 19. doi: https://doi.org/10.1038/s41541-021-00280-0
Wagstaffe HR, Susannini G, Thiébaut R, Richert L, Lévy Y, Bockstal V, Stoop JN, Luhn K, Douoguih M, Riley EM, Lacabaratz C, Goodier MR. Durable natural killer cell responses after heterologous two-dose Ebola vaccination. NPJ Vaccines. 2021 Jan 29;6(1):19. doi: 10.1038/s41541-021-00280-0. PMID: 33514756; PMCID: PMC7846750.
Copy Download .nbib Format: NLM
Breast Cancer in Togolese Women: Imaging and Clinicopathological Findings.

Breast cancer : basic and clinical research

Darré T, Tchaou M, Djiwa T, Douaguibe B, Bassowa A, Adani-Ifé S, Amavi AK, N'Timon B, Amadou A, Simgban P, N'Bortche BK, Amégbor K, Aboubakari AS, Napo-Koura G.
PMID: 34103923
Breast Cancer (Auckl). 2021 May 30;15:11782234211020242. doi: 10.1177/11782234211020242. eCollection 2021.

BACKGROUND: Breast cancer is the most common cancer in women, and its incidence and mortality rates are expected to increase significantly over the next few years, particularly in developing countries. The aim of this study was to describe the...

Cite
Darré T, Tchaou M, Djiwa T, et al. Breast Cancer in Togolese Women: Imaging and Clinicopathological Findings. Breast Cancer (Auckl). 2021;15:11782234211020242doi: 10.1177/11782234211020242.
Darré, T., Tchaou, M., Djiwa, T., Douaguibe, B., Bassowa, A., Adani-Ifé, S., Amavi, A. K., N'Timon, B., Amadou, A., Simgban, P., N'Bortche, B. K., Amégbor, K., Aboubakari, A. S., & Napo-Koura, G. (2021). Breast Cancer in Togolese Women: Imaging and Clinicopathological Findings. Breast cancer : basic and clinical research, 1511782234211020242. https://doi.org/10.1177/11782234211020242
Darré, Tchin, et al. "Breast Cancer in Togolese Women: Imaging and Clinicopathological Findings." Breast cancer : basic and clinical research vol. 15 (2021): 11782234211020242. doi: https://doi.org/10.1177/11782234211020242
Darré T, Tchaou M, Djiwa T, Douaguibe B, Bassowa A, Adani-Ifé S, Amavi AK, N'Timon B, Amadou A, Simgban P, N'Bortche BK, Amégbor K, Aboubakari AS, Napo-Koura G. Breast Cancer in Togolese Women: Imaging and Clinicopathological Findings. Breast Cancer (Auckl). 2021 May 30;15:11782234211020242. doi: 10.1177/11782234211020242. eCollection 2021. PMID: 34103923; PMCID: PMC8170281.
Copy Download .nbib Format: NLM
Publisher Correction: Identification of cell surface markers and establishment of monolayer differentiation to retinal pigment epithelial cells.

Nature communications

Reyes AP, Petrus-Reurer S, Sánchez SP, Kumar P, Douagi I, Bartuma H, Aronsson M, Westman S, Lardner E, André H, Falk A, Nandrot EF, Kvanta A, Lanner F.
PMID: 32376982
Nat Commun. 2020 May 06;11(1):2346. doi: 10.1038/s41467-020-16166-z.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Reyes AP, Petrus-Reurer S, Sánchez SP, et al. Publisher Correction: Identification of cell surface markers and establishment of monolayer differentiation to retinal pigment epithelial cells. Nat Commun. 2020;11(1):2346doi: 10.1038/s41467-020-16166-z.
Reyes, A. P., Petrus-Reurer, S., Sánchez, S. P., Kumar, P., Douagi, I., Bartuma, H., Aronsson, M., Westman, S., Lardner, E., André, H., Falk, A., Nandrot, E. F., Kvanta, A., & Lanner, F. (2020). Publisher Correction: Identification of cell surface markers and establishment of monolayer differentiation to retinal pigment epithelial cells. Nature communications, 11(1), 2346. https://doi.org/10.1038/s41467-020-16166-z
Reyes, Alvaro Plaza, et al. "Publisher Correction: Identification of cell surface markers and establishment of monolayer differentiation to retinal pigment epithelial cells." Nature communications vol. 11,1 (2020): 2346. doi: https://doi.org/10.1038/s41467-020-16166-z
Reyes AP, Petrus-Reurer S, Sánchez SP, Kumar P, Douagi I, Bartuma H, Aronsson M, Westman S, Lardner E, André H, Falk A, Nandrot EF, Kvanta A, Lanner F. Publisher Correction: Identification of cell surface markers and establishment of monolayer differentiation to retinal pigment epithelial cells. Nat Commun. 2020 May 06;11(1):2346. doi: 10.1038/s41467-020-16166-z. PMID: 32376982; PMCID: PMC7203115.
Copy Download .nbib Format: NLM
Safety and Immunogenicity of Heterologous and Homologous Two Dose Regimens of Ad26- and MVA-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.

The Journal of infectious diseases

Goldstein N, Bockstal V, Bart S, Luhn K, Robinson C, Gaddah A, Callendret B, Douoguih M.
PMID: 32939546
J Infect Dis. 2020 Sep 16; doi: 10.1093/infdis/jiaa586. Epub 2020 Sep 16.

BACKGROUND: This phase 1 placebo-controlled study assessed safety and immunogenicity of two-dose regimens of Ad26.ZEBOV (Ad26) and MVA-BN-Filo (MVA) vaccines with booster vaccination at Day 360.METHODS: Healthy US adults (N = 164) randomized into 10 groups received saline placebo,...

Cite
Goldstein N, Bockstal V, Bart S, et al. Safety and Immunogenicity of Heterologous and Homologous Two Dose Regimens of Ad26- and MVA-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study. J Infect Dis. 2020;doi: 10.1093/infdis/jiaa586.
Goldstein, N., Bockstal, V., Bart, S., Luhn, K., Robinson, C., Gaddah, A., Callendret, B., & Douoguih, M. (2020). Safety and Immunogenicity of Heterologous and Homologous Two Dose Regimens of Ad26- and MVA-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study. The Journal of infectious diseases, . https://doi.org/10.1093/infdis/jiaa586
Goldstein, Neil, et al. "Safety and Immunogenicity of Heterologous and Homologous Two Dose Regimens of Ad26- and MVA-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study." The Journal of infectious diseases vol. (2020). doi: https://doi.org/10.1093/infdis/jiaa586
Goldstein N, Bockstal V, Bart S, Luhn K, Robinson C, Gaddah A, Callendret B, Douoguih M. Safety and Immunogenicity of Heterologous and Homologous Two Dose Regimens of Ad26- and MVA-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study. J Infect Dis. 2020 Sep 16; doi: 10.1093/infdis/jiaa586. Epub 2020 Sep 16. PMID: 32939546.
Copy Download .nbib Format: NLM
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants.

bioRxiv : the preprint server for biology

Cho H, Gonzales-Wartz KK, Huang D, Yuan M, Peterson M, Liang J, Beutler N, Torres JL, Cong Y, Postnikova E, Bangaru S, Talana CA, Shi W, Yang ES, Zhang Y, Leung K, Wang L, Peng L, Skinner J, Li S, Wu NC, Liu H, Dacon C, Moyer T, Cohen M, Zhao M, Lee FE, Weinberg RS, Douagi I, Gross R, Schmaljohn C, Pegu A, Mascola JR, Holbrook M, Nemazee D, Rogers TF, Ward AB, Wilson IA, Crompton PD, Tan J.
PMID: 33821267
bioRxiv. 2021 Apr 01; doi: 10.1101/2021.04.01.437942.

The emergence of SARS-CoV-2 variants that threaten the efficacy of existing vaccines and therapeutic antibodies underscores the urgent need for new antibody-based tools that potently neutralize variants by targeting multiple sites of the spike protein. We isolated 216 monoclonal...

Cite
Cho H, Gonzales-Wartz KK, Huang D, et al. Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants. bioRxiv. 2021;doi: 10.1101/2021.04.01.437942.
Cho, H., Gonzales-Wartz, K. K., Huang, D., Yuan, M., Peterson, M., Liang, J., Beutler, N., Torres, J. L., Cong, Y., Postnikova, E., Bangaru, S., Talana, C. A., Shi, W., Yang, E. S., Zhang, Y., Leung, K., Wang, L., Peng, L., Skinner, J., Li, S., Wu, N. C., Liu, H., Dacon, C., Moyer, T., Cohen, M., Zhao, M., Lee, F. E., Weinberg, R. S., Douagi, I., Gross, R., Schmaljohn, C., Pegu, A., Mascola, J. R., Holbrook, M., Nemazee, D., Rogers, T. F., Ward, A. B., Wilson, I. A., Crompton, P. D., & Tan, J. (2021). Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2021.04.01.437942
Cho, Hyeseon, et al. "Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2021.04.01.437942
Cho H, Gonzales-Wartz KK, Huang D, Yuan M, Peterson M, Liang J, Beutler N, Torres JL, Cong Y, Postnikova E, Bangaru S, Talana CA, Shi W, Yang ES, Zhang Y, Leung K, Wang L, Peng L, Skinner J, Li S, Wu NC, Liu H, Dacon C, Moyer T, Cohen M, Zhao M, Lee FE, Weinberg RS, Douagi I, Gross R, Schmaljohn C, Pegu A, Mascola JR, Holbrook M, Nemazee D, Rogers TF, Ward AB, Wilson IA, Crompton PD, Tan J. Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants. bioRxiv. 2021 Apr 01; doi: 10.1101/2021.04.01.437942. PMID: 33821267; PMCID: PMC8020967.
Copy Download .nbib Format: NLM
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial.

The Lancet. Infectious diseases

Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Köhn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Greenwood B, Leyssen M, Douoguih M, Leigh B, Watson-Jones D.
PMID: 34529962
Lancet Infect Dis. 2021 Sep 13; doi: 10.1016/S1473-3099(21)00128-6. Epub 2021 Sep 13.

BACKGROUND: Children account for a substantial proportion of cases and deaths from Ebola virus disease. We aimed to assess the safety and immunogenicity of a two-dose heterologous vaccine regimen, comprising the adenovirus type 26 vector-based vaccine encoding the Ebola...

Cite
Afolabi MO, Ishola D, Manno D, et al. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Lancet Infect Dis. 2021;doi: 10.1016/S1473-3099(21)00128-6.
Afolabi, M. O., Ishola, D., Manno, D., Keshinro, B., Bockstal, V., Rogers, B., Owusu-Kyei, K., Serry-Bangura, A., Swaray, I., Lowe, B., Kowuor, D., Baiden, F., Mooney, T., Smout, E., Köhn, B., Otieno, G. T., Jusu, M., Foster, J., Samai, M., Deen, G. F., Larson, H., Lees, S., Goldstein, N., Gallagher, K. E., Gaddah, A., Heerwegh, D., Callendret, B., Luhn, K., Robinson, C., Greenwood, B., Leyssen, M., Douoguih, M., Leigh, B., Watson-Jones, D. (2021). Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. The Lancet. Infectious diseases, . https://doi.org/10.1016/S1473-3099(21)00128-6
Afolabi, Muhammed O, et al. "Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial." The Lancet. Infectious diseases vol. (2021). doi: https://doi.org/10.1016/S1473-3099(21)00128-6
Afolabi MO, Ishola D, Manno D, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Köhn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Greenwood B, Leyssen M, Douoguih M, Leigh B, Watson-Jones D. Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. Lancet Infect Dis. 2021 Sep 13; doi: 10.1016/S1473-3099(21)00128-6. Epub 2021 Sep 13. PMID: 34529962.
Copy Download .nbib Format: NLM
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial.

The Lancet. Infectious diseases

Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Köhn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Leyssen M, Greenwood B, Douoguih M, Leigh B, Watson-Jones D.
PMID: 34529963
Lancet Infect Dis. 2021 Sep 13; doi: 10.1016/S1473-3099(21)00125-0. Epub 2021 Sep 13.

BACKGROUND: The Ebola epidemics in west Africa and the Democratic Republic of the Congo highlight an urgent need for safe and effective vaccines to prevent Ebola virus disease. We aimed to assess the safety and long-term immunogenicity of a...

Cite
Ishola D, Manno D, Afolabi MO, et al. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. Lancet Infect Dis. 2021;doi: 10.1016/S1473-3099(21)00125-0.
Ishola, D., Manno, D., Afolabi, M. O., Keshinro, B., Bockstal, V., Rogers, B., Owusu-Kyei, K., Serry-Bangura, A., Swaray, I., Lowe, B., Kowuor, D., Baiden, F., Mooney, T., Smout, E., Köhn, B., Otieno, G. T., Jusu, M., Foster, J., Samai, M., Deen, G. F., Larson, H., Lees, S., Goldstein, N., Gallagher, K. E., Gaddah, A., Heerwegh, D., Callendret, B., Luhn, K., Robinson, C., Leyssen, M., Greenwood, B., Douoguih, M., Leigh, B., Watson-Jones, D. (2021). Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. The Lancet. Infectious diseases, . https://doi.org/10.1016/S1473-3099(21)00125-0
Ishola, David, et al. "Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial." The Lancet. Infectious diseases vol. (2021). doi: https://doi.org/10.1016/S1473-3099(21)00125-0
Ishola D, Manno D, Afolabi MO, Keshinro B, Bockstal V, Rogers B, Owusu-Kyei K, Serry-Bangura A, Swaray I, Lowe B, Kowuor D, Baiden F, Mooney T, Smout E, Köhn B, Otieno GT, Jusu M, Foster J, Samai M, Deen GF, Larson H, Lees S, Goldstein N, Gallagher KE, Gaddah A, Heerwegh D, Callendret B, Luhn K, Robinson C, Leyssen M, Greenwood B, Douoguih M, Leigh B, Watson-Jones D. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. Lancet Infect Dis. 2021 Sep 13; doi: 10.1016/S1473-3099(21)00125-0. Epub 2021 Sep 13. PMID: 34529963.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 44 entries